A female scientist in a lab

How AI can support decision-making in drug development portfolios

For the pharmaceutical industry, AI can be a powerful tool to drive better-informed asset portfolio decisions.


In brief
  • Making decisions about drug development portfolios requires synthesizing dozens of complex inputs, a process that can be made more efficient and accurate with AI.
  • By harnessing AI, the R&D portfolio office can transform its role as a strategic partner in asset prioritization decisions.

When evaluating their drug development portfolios, pharmaceutical companies traditionally have engaged in a delicate balance of scientific research, patient impact, market considerations, internal constraints and, ultimately, human judgment, with no industry-wide leading practice to guide them. The traditional role of the R&D portfolio office has been to run simulations with dozens of complex inputs and then provide two- or three-dimensional visual aids and narrative detail to decision-makers in pipeline prioritization meetings. The ability of the portfolio team to support decisions is often impaired by poor-quality program data, long turnaround times for additional analysis by program teams, and analysis and visualization tools that require significant effort to update to answer new questions.

The integration of artificial intelligence (AI) into these processes is set to transform the portfolio office. AI’s ability to process complex inputs and analyze unstructured data sets offers a more informed, efficient and strategic approach to drug development decisions. By improving data integrity and accelerating the process, AI has the potential to elevate the portfolio office to a strategic partnership with R&D and corporate leaders.

 

The AI-powered portfolio office unlocks benefits that allow for better data inputs, digital twin and virtual pipeline analytics, and real-time decision support.

As the AI ecosystem matures, proactive portfolio and program offices are already working with functional leaders to enable future AI capabilities while enhancing operational performance in the short term. Forward-thinking R&D portfolio leaders in the space are taking actions that make them more AI ready, while also addressing current state operational problems:

  • Increasing efforts to inventory and document the comprehensive set of R&D data – planning, operational, market and competitive data – used for leadership decision support and map out the needed connection points between this data to enable AI engines
  • Focusing on data integrity efforts – quality, completeness and timeliness of data – and establishing reference data sets that can be used for AI training while also building leadership trust in the data 
  • Taking a more active role in guiding the evolution of the timeline, resource and cost planning practices across the R&D organization

Having a modern R&D portfolio office that embraces AI will better equip firms to identify opportunities, predict challenges and guide strategic decision-making, ultimately speeding the delivery of innovative drugs to patients.

Yuri Chernyak and Abhishek Tondon contributed to the writing of this article.

Summary 

By improving data quality, speeding up simulations and enhancing strategic planning, AI can set a new standard for how decisions are made in pharmaceutical drug development. Integrating AI allows the portfolio office to elevate its role in helping R&D leaders make data-driven decisions on asset prioritization and acquisition to support top-line revenue growth.

About this article

Authors

Related articles

How AI agents will take GenAI from answers to actions.

AI agents know when to start a series of actions and complete them. Here are three ways to prepare today as the technology matures. Learn more.

How life sciences CIOs can make the most of GenAI investments

Optimism about GenAI is spreading among CIOs of life sciences organizations, which must focus on key priorities to benefit from the technology. Read more.

How global business leaders can harness the power of GenAI

Learn about five strategic lessons for business leaders seeking to successfully utilize the power of GenAI.